H. Lundbeck AS (FRA:LDBA) Other Stockholders Equity: €-60 Mil (As of Mar. 2026)


FRA:LDBA H. Lundbeck AS FRA:LDBA
81 GF Score
Price €5.93
GF Value €6.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is H. Lundbeck AS Other Stockholders Equity?

H. Lundbeck AS FRA:LDBA +3.13% 81 Other Stockholders Equity is €-60 Mil as of Mar. 2026. GuruFocus rates FRA:LDBA with a GF Score™ of 81/100 and a GF Value™ of €6.31 (Fairly Valued). The stock has 4 warning signs investors should review.

H. Lundbeck AS's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €-60 Mil.

H. Lundbeck AS's quarterly Other Stockholders Equity declined from Sep. 2025 (€-63 Mil) to Dec. 2025 (€-95 Mil) but then increased from Dec. 2025 (€-95 Mil) to Mar. 2026 (€-60 Mil).

H. Lundbeck AS's annual Other Stockholders Equity increased from Dec. 2023 (€157 Mil) to Dec. 2024 (€225 Mil) but then declined from Dec. 2024 (€225 Mil) to Dec. 2025 (€-95 Mil).

H. Lundbeck AS Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Other Stockholders Equity Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.75 214.26 157.24 225.27 -94.53

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.84 -42.36 -63.24 -94.53 -60.07
FRA:LDBA
81GF Score
H. Lundbeck AS FRA:LDBA
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-60 Mil mean?
H. Lundbeck AS (FRA:LDBA) has a Other Stockholders Equity of €-60 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on H. Lundbeck AS and its competitors.
Is H. Lundbeck AS's Other Stockholders Equity too high?
H. Lundbeck AS's current Other Stockholders Equity is €-60 Mil. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Other Stockholders Equity compare to ZTS and UTHR?
H. Lundbeck AS's Other Stockholders Equity of €-60 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current Other Stockholders Equity is €-60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.31, compared to a current price of €5.93 — trading 6.1% below its estimated fair value. The current Other Stockholders Equity is €-60 Mil. H. Lundbeck AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current Other Stockholders Equity is €-60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • Other Stockholders Equity: €-60 Mil
  • GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score

Get the complete analysis for FRA:LDBA

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.93
Price
€6.31
GF Value